Randel William  Woodgrift net worth and biography

Randel Woodgrift Biography and Net Worth

Randel is Abbott’s Senior Vice President, Cardiac Rhythm Management. He was appointed to this role in 2019. He previously served as Vice President, Global Operations, Cardiovascular and Neuromodulation.

Randel joined Abbott in 2012 as Divisional Vice President, Manufacturing Operations.  He began his now more than 30-year career in cardiovascular R&D at American Hospital Supply Cardiovascular Group, and subsequently held leadership positions at a variety of companies. These include Vice President, Operations at Edwards Lifesciences; Senior Vice President, Technology and Operations at Vertos Medical, and numerous positions in R&D and operations, including Vice President, Global Manufacturing, at Baxter International.

Randel earned his bachelor of science degree in Mechanical Engineering from California Polytechnic University, San Luis Obispo, California. He also holds a graduate certificate in Biomedical Engineering from University of California, Irvine and a master’s degree in Business Administration from Pepperdine University, Malibu, California.

What is Randel William Woodgrift's net worth?

The estimated net worth of Randel William Woodgrift is at least $6.15 million as of March 1st, 2023. Mr. Woodgrift owns 52,203 shares of Abbott Laboratories stock worth more than $6,147,425 as of November 22nd. This net worth approximation does not reflect any other assets that Mr. Woodgrift may own. Learn More about Randel William Woodgrift's net worth.

How do I contact Randel William Woodgrift?

The corporate mailing address for Mr. Woodgrift and other Abbott Laboratories executives is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. Abbott Laboratories can also be reached via phone at (224) 667-6100. Learn More on Randel William Woodgrift's contact information.

Has Randel William Woodgrift been buying or selling shares of Abbott Laboratories?

Randel William Woodgrift has not been actively trading shares of Abbott Laboratories within the last three months. Most recently, Randel William Woodgrift sold 1,032 shares of the business's stock in a transaction on Wednesday, March 1st. The shares were sold at an average price of $100.70, for a transaction totalling $103,922.40. Following the completion of the sale, the senior vice president now directly owns 52,203 shares of the company's stock, valued at $5,256,842.10. Learn More on Randel William Woodgrift's trading history.

Who are Abbott Laboratories' active insiders?

Abbott Laboratories' insider roster includes Hubert Allen (Executive Vice President, General Counsel and Secretary), Roxanne Austin (Director), Roger Bird (SVP), Brian Blaser (Insider), Philip Boudreau (VP), Sharon Bracken (Insider), John Capek (EVP), Jaime Contreras (SVP), Michael Dale (SVP), Lisa Earnhardt (EVP), Robert Ford (Chairman), Robert Ford (CEO), Robert Funck (CFO), Robert Funck, Jr. (EVP), Robert Funck, Jr. (EVP), Stephen Fussell (EVP), John Ginascol (EVP), Sammy Karam (SVP), Michelle Kumbier (Director), Andrew Lane (EVP), Joseph Manning (SVP), John Mccoy Jr. (VP), Nancy Mckinstry (Director), Mary Moreland (EVP), Louis Morrone (SVP), Phebe Novakovic (Director), Michael Pederson (SVP), Daniel Salvadori (EVP), Christopher Scoggins (SVP), Daniel Starks (Director), Julie Tyler (SVP), Andrea Wainer (EVP), Jared Watkin (SVP), Miles White (Chairman), Randel Woodgrift (SVP), and Brian Yoor (CFO). Learn More on Abbott Laboratories' active insiders.

Are insiders buying or selling shares of Abbott Laboratories?

During the last year, insiders at the healthcare product maker sold shares 9 times. They sold a total of 246,090 shares worth more than $28,051,118.59. The most recent insider tranaction occured on September, 12th when CEO Robert B Ford sold 141,679 shares worth more than $16,492,852.39. Insiders at Abbott Laboratories own 1.1% of the company. Learn More about insider trades at Abbott Laboratories.

Information on this page was last updated on 9/12/2024.

Randel William Woodgrift Insider Trading History at Abbott Laboratories

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/1/2023Sell1,032$100.70$103,922.4052,203View SEC Filing Icon  
5/4/2022Sell24,000$113.00$2,712,000.0047,854View SEC Filing Icon  
3/1/2022Sell964$118.10$113,848.40View SEC Filing Icon  
9/3/2021Sell6,350$129.00$819,150.0050,093View SEC Filing Icon  
3/1/2021Sell1,034$120.61$124,710.7451,495View SEC Filing Icon  
9/11/2020Sell2,500$105.28$263,200.0046,267View SEC Filing Icon  
4/28/2020Sell3,724$93.18$347,002.3248,767View SEC Filing Icon  
10/23/2019Sell21,000$80.54$1,691,340.0068,562View SEC Filing Icon  
7/24/2019Sell65,000$88.01$5,720,650.00117,562View SEC Filing Icon  
4/22/2019Buy2,000$73.40$146,800.0052,562View SEC Filing Icon  
See Full Table

Randel William Woodgrift Buying and Selling Activity at Abbott Laboratories

This chart shows Randel William Woodgrift's buying and selling at Abbott Laboratories by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Abbott Laboratories Company Overview

Abbott Laboratories logo
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Read More

Today's Range

Now: $117.76
Low: $116.38
High: $118.00

50 Day Range

MA: $115.58
Low: $112.23
High: $119.39

2 Week Range

Now: $117.76
Low: $99.71
High: $121.64

Volume

5,247,005 shs

Average Volume

5,695,718 shs

Market Capitalization

$204.25 billion

P/E Ratio

35.79

Dividend Yield

1.88%

Beta

0.72